Methimazole Clinical Trials

Size	Price	Qty
50mg	USD 147

Clinical Trials

Numerous clinical trials evaluate methimazole across Early Phase 1 through Phase 4, focusing primarily on thyroid disorders—including Graves' disease, hyperthyroidism, toxic nodular goiter, and Graves' orbitopathy—and glioblastoma multiforme. Sponsored by academic medical centers, health systems, and pharmaceutical entities, these studies reflect recruitment statuses ranging from recruiting and completed to suspended, terminated, or unknown. Investigational approaches include adjunctive nutritional interventions in pediatric cohorts and combination metabolic therapies.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06240455	SUSPENDED	Graves Disease	Worg Biotherapeutics Inc.	2026-03-31	PHASE2
NCT07369063	RECRUITING	Graves Disease; Graves' Disease; Hyperthyroidism	Northwell Health	2025-08-01	PHASE2
NCT06327828	NOT_YET_RECRUITING	Graves Disease	Medical University of Graz	2024-09-01
NCT05607407	SUSPENDED	Glioblastoma; Glioma	Case Comprehensive Cancer Center	2023-01-30	PHASE2
NCT06068179	RECRUITING	Graves' Disease	The First Affiliated Hospital of Xiamen University	2023-10-16	PHASE2; PHASE3
NCT04946123	COMPLETED	Hyperthyroidism	Lo.Li.Pharma s.r.l	2021-07-05
NCT04776993	UNKNOWN	Graves' Orbitopathy	University of Pisa	2023-03-02	PHASE3
NCT05461820	RECRUITING	Graves Disease; Relapse; Treatment; Drug Withdrawal	The First Affiliated Hospital with Nanjing Medical University	2018-05-01	PHASE4
NCT05017610	WITHDRAWN	Recurrent Glioblastoma; Recurrent Gliosarcoma	Emory University	2021-10-20	EARLY_PHASE1
NCT05118542	COMPLETED	Hyperthyroidism; Graves Disease; Atherosclerosis of Artery; Pathophysiology	Indonesia University	2019-01-01	PHASE3
NCT02654041	TERMINATED	Glioblastoma Multiforme (GBM)	Musli Thyropeutics Ltd.	2016-03	PHASE2
NCT01458600	COMPLETED	Graves´ Disease	Mikael Lantz	2006-09	PHASE4
NCT02727738	COMPLETED	Graves' Disease	University of Pisa	2014-01
NCT01849861	UNKNOWN	Healthy	Universidade Federal do Rio de Janeiro	2011-09	PHASE4
NCT01893450	TERMINATED	Graves Ophthalmopathy	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	2008-06
NCT01560299	COMPLETED	Graves Disease	Mashhad University of Medical Sciences	2010-02
NCT01849861	Unknown status	Healthy	Universidade Federal do Rio de Janeiro\|Conselho Nacional de Desenvolvimento Científico e Tecnológico	2011-09	Phase 4
NCT00150124	COMPLETED	Toxic Nodular Goitre; Graves' Disease	Steen Bonnema	2003-01	PHASE4
NCT00001421	COMPLETED	Dermatomyositis; Polymyositis	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	1995-06	PHASE2
NCT00150111	COMPLETED	Graves´ Disease; Thyroid Associated Ophthalmopathy	Odense University Hospital	2003-06	PHASE1; PHASE2
NCT00150137	COMPLETED	Toxic Nodular Goitre; Graves Disease	Odense University Hospital	2003-01	PHASE4

(data from https://clinicaltrials.gov, updated on 2025-05-08)

Check the Methimazole product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Methimazole selectively binds to and inhibits the enzyme thyroperoxidase, thereby blocking the organification of iodide and preventing the enzymatic incorporation of iodine into thyroglobulin. By suppressing the downstream biosyntheses of triiodothyronine and thyroxine in follicular cells, this inhibition lowers circulating thyroid hormone levels to relieve hyperhormonemia in clinical trial conditions including hyperthyroidism, Graves' disease, and glioblastoma multiforme.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).